Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, announced that the
Company will join the broad-market Russell 3000® and Russell
2000® Indexes. The newly reconstituted indexes take effect
after the close on Friday, June 22, 2018.
Russell US Indexes are widely used by investment managers and
institutional investors as the basis for index funds and as benchmarks
for active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell US Indexes. Russell US Indexes are part
of FTSE Russell, a leading global index provider. Rocket’s addition to
these indexes will increase the Company’s already growing visibility and
presence with institutional investors and greater financial community.
Annual Russell US Indexes reconstitution captures the 4,000 largest US
stocks as of May 11, ranking them by total market capitalization.
Membership in the Russell 3000® Index, which remains in place
for one year, means automatic inclusion in the large-cap Russell 1000®
Index or small-cap Russell 2000® Index as well as the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell US Indexes primarily by objective,
market-capitalization rankings and style attributes.
For more information on the Russell 3000® Index and the
Russell US Indexes reconstitution, go to the “Russell Reconstitution”
section on the FTSE
About Rocket Pharmaceuticals, Inc.Rocket Pharmaceuticals,
Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage
biotechnology company focused on developing first-in-class gene therapy
treatment options for rare, devastating diseases. Rocket’s
multi-platform development approach applies the well-established
lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene
therapy platforms. Rocket’s lead clinical program is a LVV-based gene
therapy for the treatment of Fanconi Anemia (FA), a difficult to treat
genetic disease that leads to bone marrow failure and potentially
cancer. Preclinical studies of additional bone marrow-derived disorders
are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte
Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis
(IMO). Rocket is also developing an AAV-based gene therapy program for
an undisclosed rare pediatric disease. For more information about
Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005045/en/